Search: WFRF:(Perez Javier)
> (2015-2019) >
PI3K inhibition res...
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
-
- Bosch Campos, Ana (author)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylära behandlingsstrategier vid bröstcancer,Forskargrupper vid Lunds universitet,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular therapeutics in breast cancer,Lund University Research Groups,Memorial Sloan-Kettering Cancer Center
-
- Li, Zhiqiang (author)
- Memorial Sloan-Kettering Cancer Center
-
- Bergamaschi, Anna (author)
- University of Illinois at Urbana-Champaign
-
show more...
-
- Ellis, Haley (author)
- Memorial Sloan-Kettering Cancer Center
-
- Toska, Eneda (author)
- Memorial Sloan-Kettering Cancer Center
-
- Prat, Aleix (author)
- Hospital Clínic of Barcelona
-
- Tao, Jessica J. (author)
- Massachusetts General Hospital
-
- Spratt, Daniel E. (author)
- Memorial Sloan-Kettering Cancer Center
-
- Viola-Villegas, Nerissa T. (author)
- Karmanos Cancer Institute
-
- Castel, Pau (author)
- Memorial Sloan-Kettering Cancer Center
-
- Minuesa, Gerard (author)
- Memorial Sloan-Kettering Cancer Center
-
- Morse, Natasha (author)
- Memorial Sloan-Kettering Cancer Center
-
- Rodón, Jordi (author)
- Autonomous University of Barcelona
-
- Ibrahim, Yasir (author)
- Vall d'Hebron University Hospital
-
- Cortes, Javier (author)
- Vall d'Hebron University Hospital
-
- Perez-Garcia, Jose (author)
- Vall d'Hebron University Hospital
-
- Galvan, Patricia (author)
- Vall d'Hebron University Hospital
-
- Grueso, Judit (author)
- Vall d'Hebron University Hospital
-
- Guzman, Marta (author)
- Vall d'Hebron University Hospital
-
- Katzenellenbogen, John A. (author)
- University of Illinois at Urbana-Champaign
-
- Kharas, Michaelz (author)
- Memorial Sloan-Kettering Cancer Center
-
- Lewis, Jason S. (author)
- Memorial Sloan-Kettering Cancer Center
-
- Dickler, Maura (author)
- Memorial Sloan-Kettering Cancer Center
-
- Serra, Violeta (author)
- Vall d'Hebron University Hospital
-
- Rosen, Neal (author)
- Memorial Sloan-Kettering Cancer Center
-
- Chandarlapaty, Sarat (author)
- Weill Cornell Medical College
-
- Scaltriti, Maurizio (author)
- Memorial Sloan-Kettering Cancer Center
-
- Baselga, José (author)
- Weill Cornell Medical College
-
show less...
-
(creator_code:org_t)
- American Association for the Advancement of Science (AAAS), 2015
- 2015
- English.
-
In: Science Translational Medicine. - : American Association for the Advancement of Science (AAAS). - 1946-6234 .- 1946-6242. ; 7:283, s. 1-11
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://europepmc.or...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Activating mutations of PIK3CA are the most frequent genomic alterations in estrogen receptor (ER)-positive breast tumors, and selective phosphatidylinositol 3-kinase a (PI3Kα) inhibitors are in clinical development. The activity of these agents, however, is not homogeneous, and only a fraction of patients bearing PIK3CA-mutant ER-positive tumors benefit from single-agent administration. Searching for mechanisms of resistance, we observed that suppression of PI3K signaling results in induction of ER-dependent transcriptional activity, as demonstrated by changes in expression of genes containing ER-binding sites and increased occupancy by the ER of promoter regions of upregulated genes. Furthermore, expression of ESR1 mRNA and ER protein were also increased upon PI3K inhibition. These changes in gene expression were confirmed in vivo in xenografts and patient-derived models and in tumors from patients undergoing treatment with the PI3Kα inhibitor BYL719. The observed effects on transcription were enhanced by the addition of estradiol and suppressed by the anti-ER therapies fulvestrant and tamoxifen. Fulvestrant markedly sensitized ER-positive tumors to PI3Kα inhibition, resulting in major tumor regressions in vivo. We propose that increased ER transcriptional activity may be a reactive mechanism that limits the activity of PI3K inhibitors and that combined PI3K and ER inhibition is a rational approach to target these tumors.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Medicinsk genetik (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Medical Genetics (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Bosch Campos, An ...
-
Li, Zhiqiang
-
Bergamaschi, Ann ...
-
Ellis, Haley
-
Toska, Eneda
-
Prat, Aleix
-
show more...
-
Tao, Jessica J.
-
Spratt, Daniel E ...
-
Viola-Villegas, ...
-
Castel, Pau
-
Minuesa, Gerard
-
Morse, Natasha
-
Rodón, Jordi
-
Ibrahim, Yasir
-
Cortes, Javier
-
Perez-Garcia, Jo ...
-
Galvan, Patricia
-
Grueso, Judit
-
Guzman, Marta
-
Katzenellenbogen ...
-
Kharas, Michaelz
-
Lewis, Jason S.
-
Dickler, Maura
-
Serra, Violeta
-
Rosen, Neal
-
Chandarlapaty, S ...
-
Scaltriti, Mauri ...
-
Baselga, José
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Medical Genetics
- Articles in the publication
-
Science Translat ...
- By the university
-
Lund University